S. 990 was signed into law last week. At first glance, it looks like it extends the life of Small Business Administration programs that are near and dear to the bottom line of many small biotechs. But somewhere along its pat through the Senate, the bill was stripped of the language that would have extended the Small Business Innovation Research (SBIR) program through Sept. 30, 2012. In its place are a few short paragraphs renewing the Patriot Act. But the title of the bill remains “To provide for an additional temporary extension of programs under the Small Business Act and...
WASHINGTON – Citing as their prime evidence Sanofi's strategy to prevent approval of Lovenox biosimilars, two senators are building a case for more disclosure of biopharma's financial ties with nonprofit medical groups, especially when those nonprofits intervene on drug approvals and safety issues.
WASHINGTON – Threats of terrorist attacks in the wake of the death of Osama bin Laden and the reality of immense natural disasters are creating a sense of urgency as government officials recognize that the U.S. is "woefully behind" in its capability to rapidly produce vaccines and develop medical countermeasures (MCM).
WASHINGTON – Google searches and all the chatter on social networking sites could become part of the adverse event analyses the FDA uses to gauge the safety of drugs and biologics once they're on the market.